Reddy J I, Cooke P J, Van Schalkwyk J M, et al. Anaphylaxis is more common with rocuronium and succinylcholine than with atracurium [J]. Anesthesiology, 2015, 122(3): 39-45.
[3]
Takazawa T, Mitsuhata H, Mertes P M. Sugammadex and rocuronium-induced anaphylaxis [J]. J Anesth, 2016, 30(2): 290-297.
[4]
Hawkins J, Khanna S, Argalious M. Sugammadex for reversal of neuromuscular blockade: uses and limitations [J]. Curr Pharm Des, 2019, 25(19): 2140-2148.
[5]
Choi S C, Han S, Kwak J, et al. Anaphylaxis induced by sugammadex and sugammadex-rocuronium complex-a case report [J]. Korean J Anesthesiol, 2020, 73(4): 342-346.
[6]
Hashimoto M, Sato Boku A, Tachi N, et al. Two Cases of Rocuronium-Induced Anaphylaxis/Anaphylactic Shock Successfully Treated With Sugammadex [J]. Anesth Prog, 2019, 66(3): 151-155.
[7]
Binczak M, Fischler M, Le Guen M. Efficacy of sugammadex in preventing skin test reaction in a patient with confirmed rocuronium anaphylaxis: a case report [J]. AA Pract, 2019, 13(1): 17-19.
[8]
Motamed C, Baguenard P, Bourgain J L. Possible mitigation of rocuronium-induced anaphylaxis after administration of sugammadex [J]. J Anaesthesiol Clin Pharmacol, 2012, 28(1): 127-128.
[9]
Kawano T, Yokoyama M. Can sugammadex encapsulation eliminate the antigenic activity of aminosteroidal neuromuscular blocking agent? [J]. J Anesth, 2011, 25(6): 953-954.
[10]
Jones P M, Turkstra T P. Mitigation of rocuronium-induced anaphylaxis by sugammadex: the great unknown [J]. Anaesthesia, 2010, 65(1): 89-90.
[11]
Reber L L, Hernandez J D, Galli S J. The pathophysiology of anaphylaxis [J]. J Allergy Clin Immunol Pract, 2017, 140(2): 335-348.
[12]
Chompunud Na Ayudhya C, Amponnawarat A, Roy S, et al. MRGPRX2 activation by rocuronium: insights from studies with human skin mast cells and missense variants [J]. Cells, 2021, 10(1): 156.
[13]
Barthel F, Stojeba N, Lyons G, et al. Sugammadex in rocuronium anaphylaxis: dose matters [J]. Br J Anaesth, 2012, 109(4): 646-647.
2022, Vol. 33 
